Why FIH oncology trials fail before they start
A perspective on site mix, protocol assumptions, activation delays, and hidden execution risk.
Insights
Signals worth reviewing before early oncology execution.
A practical resource page for public research, oncology conference signals, and our perspective on FIH execution risk. Public Apex AI articles and official sources such as ASCO, ESMO, AACR, and SITC are available as filterable source material with original links preserved.
Featured perspectives
Start with the questions sponsors usually discover too late.
These short editorial themes give the Insights page a stable point of view even when external public-source feeds are temporarily unavailable.
Site-level activation risk vs traditional feasibility
Why averages and prestige-based KOL selection can miss the operational tails that matter.
China innovation drugs going global
How global development strategy, region selection, and trial design affect credibility outside China.
How oncology site selection should differ by mechanism
Why ADCs, bispecifics, KRAS, CAR-T, radioligands, DDR assets, and TKIs should not use the same site logic.
Article library
Public research and oncology conference signals
A unified library of public Apex AI articles and official oncology meeting sources such as ASCO, ESMO, AACR, and SITC. Filter by source, topic, or keyword; cards preserve public metadata and official source links only.
Source: Conference articles · Topic: News release · 6 articles · 10 per page
AACR CEO Margaret Foti, PhD, MD (hc): Thank you for an incredible AACR Annual Meeting 2026! - AACR Annual Meeting News
The AACR Annual Meeting 2026 featured a spectacular display of the progress that is being made against cancer due to your tremendous efforts. All of you—cancer researchers, clinicians, other health care profes... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
Closing Plenary Session examined highlights from the AACR Annual Meeting 2026 - AACR Annual Meeting News
Katerina A. Politi, PhD, identified takeaways emerging from presentations in basic and translational science, including that fundamental insights into cancer biology are revealing new strategies to treat cance... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceFifth Plenary Session spotlighted new treatment modalities transforming the oncology landscape - AACR Annual Meeting News
Katayoun Rezvani, MD, PhD, chaired the session, which shone a light on radiopharmaceuticals, next-generation biologics, and cellular immunotherapy as groundbreaking therapeutic modalities for cancer, with a fo... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
Final New Drugs on the Horizon session completed the series with the last four novel molecules - AACR Annual Meeting News
Presenters described a first-in-class inhibitor of cyclin A/B-substrate interaction, a molecular glue degrader for the treatment of acute myeloid leukemia, a novel antibody-drug conjugate, and a dual T-cell ag... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source
Fourth Plenary Session explored generational trends and possible drivers of early-onset cancers - AACR Annual Meeting News
Andrew T. Chan, MD, MPH, chaired the session, which examined the rising incidence of early-onset cancers and the potential contributions of obesity, bacterial exposures, and weaning to this trend. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official sourceSecond New Drugs on the Horizon session featured first disclosure of four more innovative therapeutics - AACR Annual Meeting News
The session spotlighted a human-sialidase-armed antitumor antibody, a novel CDK2 inhibitor, a molecular glue degrader, and a dual-payload antibody-drug conjugate. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
Open official source